Background and Rationale Ocrelizumab is a monoclonal antibody approved for the treatment of primary progressive multiple sclerosis (PPMS) and relapsing […]
Ocrelizumab-induced colitis acutely managed with ciclosporin Read Post »
Background on Pseudohypacusis Pseudohypacusis, often referred to as non-organic hearing loss, poses a unique challenge in audiology. It describes a
Study Overview The exploration of tumefactive demyelinating disorders reveals these conditions as compelling mimics of neoplastic processes, often leading to
Clinical Presentation Pseudohypacusis, commonly referred to as non-organic hearing loss, presents a unique challenge in clinical settings. Individuals may exhibit
Understanding Pseudohypacusis Pseudohypacusis refers to a condition where a person demonstrates apparent hearing loss that cannot be attributed to any
Patient Characteristics This cohort study involved a diverse group of participants diagnosed with pseudohypacusis, a condition where individuals exhibit hearing
Pseudohypacusis Characteristics Pseudohypacusis, often referred to as factitious hearing loss, is characterized by an apparent discrepancy between a patient’s reported
Study Overview This research focuses on pseudohypacusis, a condition characterized by a discrepancy between a patient’s reported hearing difficulties and
Study Overview The research focuses on the intricate relationship between functional or dissociative seizures and their manifestation in patients with
Study Overview The study investigates the complex relationship between functional or dissociative seizures and eyelid myoclonia in patients diagnosed with
